Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0

The Minority Health Genomics and Translational Research BIo-Repository Database (MH-GRID)-2.0

Background:

- High blood pressure is a common problem. It can cause heart attacks, strokes, and kidney failure. It affects African Americans more than other racial groups. Data were collected from over a thousand African Americans across the country. The data were put into a database (MH-GRID). The data were about genes, diet, sleep, body mass index. They also cover stress and access to healthy foods and parks. Researchers at NIH will study these data in new ways. They want to learn more about the connection between African Americans and high blood pressure.

Objective:

- To study MH-GRID data to find the causes of severe high blood pressure and other cardio-metabolic problems in people of African ancestry.

Eligibility:

- African Americans age 30 55 with severe high blood pressure were used in the MH-GRID study. No new participants will be enrolled in this study.

Design:

- Researchers will examine data from the MH-GRID study.

Study Overview

• Status: Completed
• Conditions: Hypertension

Detailed Description

The etiology of racial/ethnic differences in health involves dynamic interactions between

genetic, behavioral and social-environmental determinants. Despite this, the field lacks robust

datasets that integrate these determinants with clinical assessments in minority patient cohorts. The Minority Health Genomics and Translational Research Bio-repository Database (MHGRID) Network infrastructure facilitated the collection of biospecimens and related multidimensional data elements within a consortium of minority-serving clinics. This initiative expands the diversity of ancestral groups in national genomic medicine datasets and promises to accelerate the translation of personalized medicine into minority communities. The MH-GRID project was initiated by Dr. Gibbons (founding PI) prior to becoming an NIH investigator. The MH-GRID project has completed its participant recruitment activities, closed out its NIH funding and now represents an existing dataset and biorepository that is being transferred to NHGRI for ongoing secondary analyses. A variety of investigations will be conducted on this existing dataset. The primary outcome variables include severe hypertension and hypertension induced kidney damage. Secondary outcome variables include obesity, coronary heart disease and metabolic disease syndrome. Intervening variables include genetics, behavioral (i.e. sleep quality, health literacy, smoking, diet, body mass index), ancestry, social (i.e. socioeconomic status, racial discrimination, stress, social depreivation), biological (i.e. insulin resistance, cholesterol, inflammatory markers), and environmental (i.e. neighborhood, access to healthy foods, parks).

• Study Type: Observational
• Enrollment (Actual): 1692

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Bethesda, Maryland, United States, 20892
      • National Human Genome Research Institute (NHGRI)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years to 55 years (Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Description

• INCLUSION CRITERIA:
• The MH-GRID Project s inclusion criteria included AA age 30-55 years
• Severe controlled HTN or severe resistant HTN.

EXCLUSION CRITERIA:

• Exclusion criteria involved patients with secondary forms of HTN, primary forms of kidney disease or major co-morbidities (e.g. diabetes, heart failure, end-stage renal failure, HIV, and liver disease).
• Children <18 were not enrolled in the protocol.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
1; African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To complete the original MH-GRID primary outcome analyses by defining the genetic, behavioral , and social-environmental determinants of severe hypertension and other cardio-metabolic disorders in individuals of African ancestry.	To complete the original MH-GRID primary outcome analyses by defining the genetic, behavioral , and social-environmental determinants of severe hypertension and other cardio-metabolic disorders in individuals of African ancestry.	one time analysis

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The secondary outcome variables include obesity, coronary heart disease and metabolic disease syndrome. Intervening variables include genetics, behavioral, ancestry, social, biological, and environmental.	The secondary outcome variables include obesity, coronary heart disease and metabolic disease syndrome. Intervening variables include genetics, behavioral, ancestry, social, biological, and environmental.	one time analysis

Collaborators and Investigators

• Sponsor: National Human Genome Research Institute (NHGRI)
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: Amadou Gaye, M.D., National Human Genome Research Institute (NHGRI)

Study record dates

Study Major Dates

• Study Start: November 11, 2014
• Primary Completion (Actual): July 16, 2019
• Study Completion (Actual): July 16, 2019

Study Registration Dates

• First Submitted: November 11, 2014
• First Submitted That Met QC Criteria: November 11, 2014
• First Posted (Estimated): November 14, 2014

Study Record Updates

• Last Update Posted (Actual): April 4, 2024
• Last Update Submitted That Met QC Criteria: April 3, 2024
• Last Verified: February 2, 2024

More Information

Terms related to this study

• Keywords: Natural History; African American
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Hypertension
• Other Study ID Numbers: 999915011; 15-HG-N011

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No